Idexx Laboratories (IDXX) Stock News
$IDXX · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on Idexx Laboratories (IDXX) in the past 30 days, 1 of it high impact. BORSA’s news read on IDXX is bullish at 77/100, based on 1 company event over the past 7 days.
The wire on $IDXX
newest first · updated · direct subject stories onlyIDEXX Laboratories reported Q3 revenue of $1.214 billion, up 10% as reported and organic, and EPS of $4.01, up 18% as reported and 22% on a comparable basis. CAG Diagnostics recurring revenue grew 11% as reported and organic. The company raised its 2026 revenue guidance to $4.741-$4.767 billion and EPS outlook to $14.96-$15.16.
bullish 80 · impact 70The wire on this name is open. What the tape did about it is one free account away.
One free account opens every story complete, the live board and the 30-day calendar, and 3 complete ticker and report views a day. No card. The wire stays free to read.
Idexx Laboratories (IDXX) stock: common questions
What is the latest Idexx Laboratories stock news?
The highest-impact IDXX story BORSA published in the past 30 days:
· IDEXX Laboratories Q3 revenue $1.21B, EPS $4.01; lifts 2026 outlook